Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Prevention of Radiotherapy and Chemotherapy Induced Oromucosal Wounds Using an Oral Application Gel: Murnia® Mouth Gel

Project description

Advancing solutions for oral mucositis in cancer patients

Cancer patients undergoing chemotherapy or radiotherapy often suffer from debilitating side effects, including oral mucositis (OM), a painful condition causing inflammation and ulceration of the mucosal membranes in the mouth. This condition affects 40-100 % of patients, especially those receiving treatment for head and neck cancers. Current treatment options for OM are largely ineffective or come with significant side effects, resulting in prolonged cancer treatments, increased healthcare costs and a diminished quality of life for patients. The EU-funded Murnia project is advancing novel formulations aimed at both preventing and curing OM, enhancing patients' quality of life and ensuring uninterrupted cancer therapy.

Objective

Cancer is a devastating and costly condition expected to increase significantly by 2030. According to the 2018 WHO report, the global cancer burden is estimated at 18.1 million new cases annually . Mucositis is a condition in cancer patients that manifests as severe ulcerations in the mouth and the gastrointestinal tract. Oral mucositis (OM) is cancer treatment's most significant side effect worldwide .

Mucositis can be caused by chemotherapy and/or radiotherapy. It occurs in nearly 40% of patients receiving conventional CT, 80% receiving high-dose CT as conditioning for haematopoietic stem cell transplantation, and 100% receiving H&N radiation therapy, with 65% of those progressing to severe grade levels with significant adverse outcomes.

The problem with OM is that while current therapies are focussed on dealing with its symptoms like inability to eat or significant pain, there is no real cure or prevention for OM itself. Existing products in the market for OM mainly offer symptom management focusing on pain or, at best, duration reduction claims. The one approved drug for chemotherapy and radiotherapy, Amifostine, has severe side effects and tumour protective properties, making it hard to use as it interferes with the actual cancer treatment. Kepivance, which is only approved for haematological malignancies, is challenging to administer, posing compliance issues and does not solve the more significant need for solid tumours.

Umayana has developed a proprietary preventative and curative formulation to combat OM in cancer patients.
Global Patent: WO2020072987 USA Patent: 11331360 (B2).

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-CSA - HORIZON Coordination and Support Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIE-2022-SCALEUP-02

See all projects funded under this call

Coordinator

UMAYANA ARASTIRMA GELISTIRME VE ILAC SANAYI ANONIM SIRKETI
Net EU contribution
€ 75 000,00
Address
SANAYI MAH TEKNOPARK BUL 1/4C II C KAPI 208 PENDIK
34906 Istanbul
Türkiye
SME
Yes
Region
İstanbul İstanbul İstanbul
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data